Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs, Inc. President and COO Gajendra Sanjay reported automatic tax-related share sales. On 2026-05-18, Form 4 shows the sale of 95,444 shares of Astera Labs common stock in multiple open-market transactions at prices between $216.10 and $235.94 per share.
According to a footnote, these sales were required to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units and were executed under a pre-arranged “sell to cover” election, rather than as discretionary trades. Additional entries show large indirect holdings in three estate planning trusts, for which Sanjay disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of company stock tied to tax withholding. On May 18, 2026, he sold a total of 14,076 shares of Astera Labs common stock in open-market transactions.
According to the footnotes, these shares were required to be sold to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. The company had elected in advance to use a “sell to cover” method, so the trades were automatic rather than discretionary. The shares were sold at weighted-average prices within ranges that span from about $216.10 to $235.94 per share.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported open‑market sales of 139,951 shares of Common Stock, carried out on behalf of a living trust. The sales occurred at weighted average prices within ranges between $210.0564 and $250.0100 per share.
The filing states these transactions were executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2025. The shares are held through a living trust and several estate planning trusts, for which the reporting person disclaims beneficial ownership except for any pecuniary interest.
ALAB submitted a Form 144 disclosing proposed and recent sales of Common Stock by a selling holder. The filing lists restricted stock vesting under a registered plan with vesting date 05/15/2025 in amounts 5,081, 1,502, and 1,846 shares. It also records a sale by TATE 1997 LIVING TRUST of 49,665 shares on 05/14/2026 for $11,234,674.95.
Form 144 notice: proposed sale of Common Stock. The filing lists a proposed sale of 40,000 shares with an associated value of $8,623,200.00 and a filing date of 05/19/2026. The excerpt also reports prior 10b5-1 sales on 05/07/2026 totaling 280,000 shares (examples: 40,000; 200,000; 40,000) with proceeds shown in the filing.
The notice identifies the securities as Common stock and records the original acquisition date as 11/21/2017 by private acquisition from the issuer or an affiliate. The excerpt lists trustee names and addresses associated with the prior 10b5-1 sales. This filing is a regulatory notice of a proposed sale; timing and cash-flow recipients are set by the selling holder information in the filing.
ALAB - Form 144 notice of proposed sale of restricted/common shares. The filing lists 40,000 shares of Common stock to be sold under Rule 144 with an aggregate dollar amount of $8,623,200.00. The filing notes prior 10b5-1 sales during the past three months totaling 280,000 shares across named trusts with aggregate proceeds recorded.
The securities to be sold were acquired 11/21/2017 (private acquisition from issuer or affiliate). The filing date shown is 05/19/2026 and sales listed as effected on 05/07/2026 for the prior transactions.
ALAB affiliate submits Form 144 to sell 200,000 shares. The filing lists 200,000 shares of Common stock associated with a sale and includes a $43,116,000.00 figure and an outstanding share count of 171,407,939 as shown in the excerpt.
The filing also records prior 10b5-1 sales on 05/07/2026 of 40,000, 200,000, and 40,000 Common shares with corresponding reported proceeds. The filing identifies the trades as connected to trusts and notes a Private Acquisition from Issuer or an Affiliate dated 11/21/2017.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara acquired additional company stock through an employee purchase program. On May 14, 2026, he received 131 shares of common stock at $120.1815 per share under the 2024 Employee Stock Purchase Plan, bringing his direct holdings to 118,215 shares. The filing notes these plan purchases were exempt under Rule 16b-3(d) and Rule 16b-3(c).
ALAB submitted a Form 144 disclosure listing proposed resale of common stock and several previously issued restricted stock grants. The filing shows two reported open-market dispositions by Philip Mazzara of 10,000 shares each on 03/02/2026 and 04/01/2026, with proceeds of $1,174,740.60 and $1,077,662.85, respectively. The excerpt also lists restricted stock issuances dated 08/15/2024, 11/15/2023, 02/15/2024, 08/15/2023, and 05/15/2024 with individual share counts shown.
ALAB notice under Form 144 reports proposed sales tied to restricted stock vesting and multiple dispositions by Michael Truett. The filing lists vesting entries of 29,937, 12,020, 7,014, and 694 shares with vesting dates in 2024 and 2025. The filing also discloses sales by Michael Truett on 02/17/2026 of 4,250, 3,556, 2,281, 1,161, and 753 shares, each with accompanying dollar amounts reported.